参麦注射液和红花注射液治疗肺源性心脏病急性发作并心力衰竭的疗效观察

Treating acute pulmonary heart attack plus heart failure with the Shenmai injection and the Honghua injection

目的:探讨参麦注射液与红花注射液联合治疗肺源性心脏病急性发作并心力衰竭的临床疗效。方法:将我院在2010年5月-2013年5月收治的156例肺源性心脏病急性发作并心力衰竭患者,随机均分为观察组和对照组,每组各78例。对照组患者采用西医常规治疗方法,观察组患者在西医常规治疗的基础上采用静脉滴注参麦注射液和红花注射液进行治疗,比较分析两组患者的临床效果。结果:经治疗后,观察组总有效率(89.74%)显著高于对照组的总有效率(73.08%),两组间差异极显著(x2=7.1583,P<0.01);同时,观察组患者的血浆黏度、纤维蛋白原和红细胞压积水平均显著低于对照组,两组间差异极显著(分别t=49.8538、25.1266、39.4892,均P<0.01),结果具有统计学意义。结论:在常规西医治疗的基础上加用参麦注射液和红花注射液治疗肺源性心脏病急性发作并心力衰竭疗效显著,不良反应少,安全可靠,值得在临床推广使用。

Objective： To investigate the Shenmai injection and the Honghua injection for acute pulmonary heart attack plus heart failure. Methods： 156 cases of acute pulmonary heart disease were randomly divided into the observation group and the control group, 78 cases in each group. In the control group they were treated with conventional western medicine treatment, patients in the observation group were given the Shenmai injection and the Honghua injection treatment. Results： After treatment, the total efficiency in the observation group（89.74%） was significantly higher than the overall response rate（73.08%）, the difference between two groups was significant（x^2 = 7.1583, P〈0.01）; at the same time, in the observation group, plasma viscosity, fibrinogen and hematocrit water were significantly lower than those in the control group, the difference was significant（respectively t = 49.8538,25.1266,39.4892, all P〈0.01）. Conclusion： The Shenmai injection plus the Honghua injection for acute pulmonary heart attack can make significant effect on heart failure, with little adverse reactions, is safe, reliable, and worthy of clinical application.